Mu Cheng
Education
M.P.H., biostatistics, Yale School of Public Health; B.S., applied mathematics, University of California, Los Angeles
Summary of Experience
Ms. Cheng specializes in clinical and economic outcomes research across multiple disease areas, including oncology, neurology, respiratory diseases, cardiovascular diseases, and rare diseases. She provides expertise in the application of biostatistics and epidemiologic methods, particularly in health economics and outcomes research (HEOR), pharmacoepidemiology, and pharmacovigilance. Her work leverages diverse health data sources such as insurance claims, medical chart reviews, electronic medical records, and clinical trial data. Ms. Cheng has supported studies addressing key questions in treatment effectiveness, safety, and health care resource utilization and costs, contributing to evidence generation that informs clinical and policy decision-making. Her research has been presented at conferences and published in peer-reviewed journals.
-
Seizure burden and healthcare resource utilization among people living with drug-resistant focal epilepsy in the United States
Current Medical Research and Opinion, 2024
2024Mao J, Song Y, Cheng M, Xu C, Boca A, Dandurand A, Takahashi K
-
Real-world anti-seizure treatment and adverse events among individuals living with drug-resistant focal epilepsy in the United States
Epilepsia Open, 2024
2024Mao J, Takahashi K, Cheng M, Xu C, Boca A, Song Y, Dandurand A
-
Real-world perioperative treatment patterns and burden of recurrent disease in patients with high-risk endometrial cancer: a SEER-Medicare study
Journal of Medical Economics, 2024
2024Prabhu VS, Kponee-Shovein K, Cheng M, Hong JL, Song Y, Sun Y, Hilts A, Hua Q, Lichfield J, Linda R Duska LR
-
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States
Journal of Managed Care & Specialty Pharmacy, 2024
2024Ailawadhi S, Cheng M, DerSarkissian M, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Cherepanov D
-
Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data
Current Problems in Cancer, 2024
2024Ailawadhi S, Cheng M, Cherepanov D, DerSarkissian M, Stull DM, Hilts A, Chun J, Duh MS, Sanchez L
-
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States
Journal of Managed Care & Specialty Pharmacy, 2023
2023Sanchez L, Chari A, Cheng M, Cherepanov D, DerSarkissian M, Huang F, Stull DM, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Ailawadhi S
-
Network Meta-Analysis of Efficacy of Ixazomib, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Hematology, 2023
2023DerSarkissian M, Cranmer H, Dabora J, Bocharova I, Cherepanov D, Cheng M, Bhak RH, Duh MS
-
Clinical and Cost Benefits of Anti-Obesity Medication for Us Veterans Participating in the MOVE! Weight Management Program
Population Health Management, 2023
2023Garvey WT, Cheng M, Ramasamy A, Smolarz BG, Park S, Kumar N, Kim N, DerSarkissian M, Bhak RH, Duh MS, Wu M, Hansen S, Young-Xu Y
-
Profiling Disease and Economic Burden in CRSwNP Using Machine Learning
Journal of Asthma and Allergy, 2022
2022Bhattacharyya N, Silver J, Bogart M, Kponee-Shovein K, Cheng WY, Cheng M, Cheung HC, Duh MS, Hahn B
-
Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe
Crohn's & Colitis 360, 2022
2022Huynh L, Hass S, Peyrin-Biroulet L, Duh MS, Sipsma H, Cheng M, Lax A, Nag A
-
The acute effects of azithromycin use on cardiovascular mortality as compared with amoxicillin-clavulanate in US Veterans
Pharmacoepidemiology and Drug Safety, 2022
2022DerSarkissian M, Young-Xu Y, Duh MS, Bhak RH, Palmetto N, Mortensen E, Anzueto A, Nguyen C, Cheng M, Frajzyngier V, Park S, Lax A, Weatherby LB, Walker AM
-
Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center
Prostate Cancer and Prostatic Diseases, 2020
2020McKay R, Silver R, Bhak RH, Korves C, Cheng M, Appukkuttan S, Simmons SJ, Duh MS, Taplin M
-
August 26, 2024
-
December 7, 2022
-
August 30, 2022